![]() Recent trends in the management of desmoid tumors. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Adult desmoid tumors: biology, management and ongoing trials. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Kasper B, Baumgarten C, Garcia J, et al.See how desmoid tumors may infiltrate patients’ lives below. As desmoid tumors locally invade the bodies of patients, the physical toll can feel almost impossible to escape, and is often magnified by psychological, emotional, social, and even professional burdens 19,22,23.Patients may experience severe pain, limited function and mobility, and compromised quality of life 19,21.See images of tumor specimens post-resection The true borders of desmoid tumors may not be identifiable as they can infiltrate surrounding tissue, compressing muscles, nerves, and vessels, and complicating attempts to obtain clean margins without leading to morbidity 5,9,20.“Benign” can also suggest a manageable course of treatment, which may not be true for your patients 7.Because of their histology and inability to metastasize, desmoid tumors are sometimes described as “benign.” 7,19 However, that description can understate their potential impact on patients’ daily lives.Among the patients on initial observation for whom serial MRIs were available, there were 14 of 24 (58%) who underwent active treatment that did not experience tumor growth as defined by RECIST criteria.Ĭalling desmoid tumors “benign” is misleading Primary or recurrent desmoid patients (n=160) were identified retrospectively from an institutional database. Worsening impact on daily living (eg, functional impairment) 6,17,18.See desmoid tumor radiology and pathology ![]() Tumor growth documented by MRI or CT 6,17,18.16,† In order to help improve patient outcomes, healthcare providers should assess for progression as early as possible with at least one of the following: In a study conducted at Memorial Sloan Kettering Cancer Center, 58% of patients with desmoid tumors converted from active surveillance to first-line treatment without radiographic tumor progression. 13 In fact, evidence of pain can be a prognostic indicator of progression and can be associated with worse outcomes. Symptomatic progression may precede radiographic progression. Progression can be symptomatic and/or radiographic. Knowing how to identify desmoid tumor progression can lead to timely initiation of appropriate treatment Growth factors released during wound healing that promote beta-catenin activation may lead to recurrence of desmoid tumors 9,12.The pathogenesis of desmoid tumors is thought to be linked to dysregulated wound healing after trauma, such as childbirth, injury, or invasive surgery 5,9-11.Factors associated with local recurrence postsurgery include tumor location, age of the participant, and tumor size. Sometimes referred to as aggressive fibromatosis or desmoid fibromatosis, these mesenchymal tumors can be serious, debilitating and, in rare cases when vital organs are impacted, they can be life-threatening 2,6,7īased on retrospective, observational data.Although they do not metastasize, desmoid tumors are associated with local recurrence rates ranging from 24% to 77% after surgical resection 4,5,*.Desmoid tumors are locally aggressive, potentially morbid tumors of the soft tissues, with a tendency to infiltrate surrounding structures 1-3.Patients with desmoid tumors seek both disease control and symptom improvement
0 Comments
Leave a Reply. |